Emma Eriksson
YOU?
Author Swipe
View article: Atomic-level structure of the amorphous drug atuliflapon <i>via</i> NMR crystallography
Atomic-level structure of the amorphous drug atuliflapon <i>via</i> NMR crystallography Open
We determine the complete atomic-level structure of the amorphous form of the drug atuliflapon, a 5-lipooxygenase activating protein (FLAP) inhibitor, via chemical-shift-driven NMR crystallography.
View article: Transferability of Human and Environmental Microbiome on Clothes as a Tool for Forensic Investigations
Transferability of Human and Environmental Microbiome on Clothes as a Tool for Forensic Investigations Open
Considering the growing importance of microbiome analyses in forensics for identifying individuals, this study explores the transfer of the skin microbiome onto clothing, its persistence on fabrics over time, and its transferability from t…
View article: CD40 stimulation via CD40 ligand enhances adenovirus‐mediated tumour immunogenicity including ‘find‐me’, ‘eat‐me’, and ‘kill‐me’ signalling
CD40 stimulation via CD40 ligand enhances adenovirus‐mediated tumour immunogenicity including ‘find‐me’, ‘eat‐me’, and ‘kill‐me’ signalling Open
Immunostimulatory gene therapy using oncolytic viruses is currently evaluated as a promising therapy for cancer aiming to induce anti‐tumour immunity. Here, we investigate the capacity of oncolytic adenoviruses (LOAd) and their transgenes …
View article: Figure S2 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Figure S2 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Supplementary Figure S2. Oncolysis over time The human PaCa3 cell line was infected with 100MOI LOAd(-), LOAd700 or LOAd703 virus, or left uninfected. The cells were plated in a 96-well plate in quadruplicates and analyzed by MTS assay at …
View article: Figure S3 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Figure S3 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Supplementary Figure S3. Gemcitabine titration Human pancreatic cancer cell lines were cultured in increasing concentrations of gemcitabine and subjected to MTS viability assay at 72 hours post culture initiation.
View article: Figure S1 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Figure S1 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Supplementary Figure S1. Schematic figure The LOAd703 genome is displayed in the Figure. The adenovirus serotype 5 genome was modified to include E2F sites and a Sp-1 site upstream of E1A. The E1A has the delta 24 deletion. Further E3 was …
View article: Figure S2 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Figure S2 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Supplementary Figure S2. Oncolysis over time The human PaCa3 cell line was infected with 100MOI LOAd(-), LOAd700 or LOAd703 virus, or left uninfected. The cells were plated in a 96-well plate in quadruplicates and analyzed by MTS assay at …
View article: Data from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Data from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Purpose: Pancreatic cancer is a severe indication with short expected survival despite surgery and/or combination chemotherapeutics. Checkpoint blockade antibodies are approved for several cancer indications, but pancreatic cancer has rema…
View article: Figure S3 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Figure S3 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Supplementary Figure S3. Gemcitabine titration Human pancreatic cancer cell lines were cultured in increasing concentrations of gemcitabine and subjected to MTS viability assay at 72 hours post culture initiation.
View article: Figure S1 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Figure S1 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Supplementary Figure S1. Schematic figure The LOAd703 genome is displayed in the Figure. The adenovirus serotype 5 genome was modified to include E2F sites and a Sp-1 site upstream of E1A. The E1A has the delta 24 deletion. Further E3 was …
View article: Data from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Data from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus Open
Purpose: Pancreatic cancer is a severe indication with short expected survival despite surgery and/or combination chemotherapeutics. Checkpoint blockade antibodies are approved for several cancer indications, but pancreatic cancer has rema…
View article: Supplementary Figures 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
Supplementary Figures 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice Open
Supplementary Figures 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
View article: Supplementary Figures 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
Supplementary Figures 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice Open
Supplementary Figures 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
View article: Data from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
Data from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice Open
Proteasome inhibitors (PI), a novel class of anticancer drugs, are relatively well tolerated and have recently been introduced into the clinic for the treatment of multiple myeloma. The tumor selectivity and low toxicity of PIs are surpris…
View article: Data from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
Data from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice Open
Proteasome inhibitors (PI), a novel class of anticancer drugs, are relatively well tolerated and have recently been introduced into the clinic for the treatment of multiple myeloma. The tumor selectivity and low toxicity of PIs are surpris…
View article: Supplementary Figure Legends 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
Supplementary Figure Legends 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice Open
Supplementary Figure Legends 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
View article: Supplementary Figure Legends 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
Supplementary Figure Legends 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice Open
Supplementary Figure Legends 1-7 from Proteasome Inhibition Up-regulates p53 and Apoptosis-Inducing Factor in Chondrocytes Causing Severe Growth Retardation in Mice
View article: A Comparison of Strategies to Improve Uptake of COVID-19 Vaccine among High-Risk Adults in Nairobi, Kenya in 2022
A Comparison of Strategies to Improve Uptake of COVID-19 Vaccine among High-Risk Adults in Nairobi, Kenya in 2022 Open
Background: COVID-19 vaccine uptake in Kenya is still low compared to other countries, especially in Europe and North America. In most parts of the country, a large percentage of the Kenyan population remains unvaccinated. As of October 20…
View article: Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas–Long-Term Follow Up
Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas–Long-Term Follow Up Open
Malignant melanoma is a serious disease in both humans and dogs, and the high metastatic potential results in poor prognosis for many patients. Its similarities with human melanoma make spontaneous canine melanoma an excellent model for co…
View article: Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy Open
Pretreatment of B-cell lymphoma patients with immunostimulatory gene therapy using armed oncolytic viruses may prime tumor lesions for subsequent chimeric antigen receptor (CAR) T-cell therapy, thereby enhancing CAR T-cell functionality an…
View article: Targeting Tumor-Induced Immunosuppression Using Conventional Cancer Therapeutics
Targeting Tumor-Induced Immunosuppression Using Conventional Cancer Therapeutics Open
Immunosuppression remains a challenge in the immunotherapy field and needs to be combated to increase survival of patients suffering from cancer. There have been no phase III trials that have in an organized, statistically reliable setting…
View article: Different perspectives of deforestation in the Peruvian Amazon : An interview study based in Cusco and Pilcopata in the Cusco region
Different perspectives of deforestation in the Peruvian Amazon : An interview study based in Cusco and Pilcopata in the Cusco region Open
The Amazon rainforest constitutes a quarter of the global biodiversity and is responsible for 15% of the terrestrial photosynthesis. It is important to protect the forest and limit the deforestation to not release more greenhouse gases, wh…
View article: Immunostimulatory AdCD40L gene therapy in patients with advanced solid tumours
Immunostimulatory AdCD40L gene therapy in patients with advanced solid tumours Open
Background: CD40-CD40L is a key activator of adaptive immunity. AdCD40L is a replication-deficient adenovirus carrying the CD40 ligand gene. We have conducted a phase I/II study (NCT01455259) for patients with advanced cancer receiving int…